<!DOCTYPE html><html ng-app="cds_app">
<head>
<title>{{def.concept.name}}</title>
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<link rel="stylesheet" type="text/css" href="wro/foundation.css"/>
<link rel="stylesheet" type="text/css" href="wro/date-picker.css"/>
<link rel="stylesheet" type="text/css" href="wro/angular.css"></link>
<script type="text/javascript" src="wro/angular.js"></script>
<link rel="text/javascript" type="text/css" href="wro/foundation.js"/>
<script type="text/javascript" src="wro/moment.js"></script>
<script type="text/javascript" src="wro/date-picker.js"></script>
<script type="text/javascript" src="wro/app_lib.js"></script>
<script id="decision-support-view" type="application/json">{
  "dsViewId": "TNM_breast_cancer.v1",
  "language": {
    "originalLanguage": {
      "terminologyId": {
        "name": "ISO_639-1",
        "value": "ISO_639-1"
      },
      "codeString": "en"
    }
  },
  "decisionSupportViewDefinitions": {
    "sv": {
      "name": "TNM Bröstcancer",
      "description": "American Joint Committee on Cancers TNM-klassifikation för bröstcancer"
    },
    "en": {
      "name": "TNM Breast Cancer",
      "description": "The American Joint Committee on Cancer (AJCC) TNM staging system for breast cancer"
    }
  },
  "resourceDescription": {
    "originalAuthor": {
      "date": "2017-06-16",
      "name": "Syeeda S Farruque",
      "organisation": "Cambio Healthcare Systems",
      "email": "syeeda.farruque@cambiocds.com"
    },
    "otherContributors": [
      "Dennis Forslund, Cambio Healthcare Systems"
    ],
    "details": {
      "sv": {
        "purpose": "American Joint Committee on Cancers (AJCC) TNM-klassifikation beskriver allvarlighetsgrad av bröstcancer baserat på tumörstorlek, lymfkörtelengagemang och förekomst av metastaser.",
        "keywords": [
          "TNM",
          "TNM-klassifikation",
          "bröstcancer",
          "cancer",
          "onkologi"
        ],
        "use": "TNM-klassifikation används för bröstcancer efter genomförd biopsi, med syfte att stadieindela och få prognostisk information. Riktlinjerna uppdateras kontinuerligt av National Comprehensive Cancer Network (3). \n\nStadieindelningen av bröstcancer inkluderar detaljerade subgrupper vilka i korthet beskrivs nedan. För vidare detaljer, vänligen se AJCC:s information (1). \n\nStadieindelningen baseras på följande grundläggande faktorer:\n\n•Primärturmör (T)\n•Regionalt lymfkörtelengagemang (N) \no    Kliniskt\no    Patologiskt\n•Fjärrmetastaser (M)\n\nT\nTX: primärtumör kan inte fastställas.\nT0: ingen primärtumör påvisad.\nTis: Carcinoma in situ (DCIS, LCIS, eller Pagets sjukdom utan associerad tumör)\nT1 (inkluderar T1a, T1b, och T1c): tumören är 2 cm eller mindre.\nT2: tumören är större än 2 cm men inte större än 5 cm.\nT3: tumören är större än 5 cm.\nT4 (inkluderar T4a, T4b, T4c, och T4d): tumör som oavsett storlek invaderat bröstväggen eller hud. Inflammatorisk bröstcancer ingår i detta stadium.\n\nN\nEtt område av spridd cancer \u003c0,2mm (eller färre än 200 celler) påverkar inte stadieindelningen. Dessa registreras med förkortningar (i+ eller mol+) vilka indikerar vilken sorts test som användes för att lokalisera spridningen. \n\nOm området av spridd cancer istället är \u003d 0,2mm (eller 200 celler), men inte större än 2 cm, kallas det mikrometastas. Dessa räknas endast om det inte finns större områden av spridd cancer (\u003e2cm).\n\nNX: regionalt lymfkörtelengagemang kan ej fastställas.\nN0: inga tumörceller har kunnat påvisas i regionala lymfkörtlar.\nN0(i+): spridning påvisad med immunhistokemi, \u003c200 celler och \u003c0,2mm [“i+” \u003d förekomst av lågt antal isolerade tumörceller].\nN0(mol+): cancerceller kan ej lokaliseras i regionala lymfkörtlar men spår av cancerceller har påvisats genom bruk av RT-PCR.\nN1: spridning till 1-3 lymfkörtlar i axillen, och/eller mindre massa cancer i bröstets lymfkörtlar.\nN1mi: mikrometastaser i 1-3 lymfkörtlar i axillen; som mest 2mm stora områden (men minst 200 celler/0,2mm).\nN1a: spridning till 1-3 av axillens lymfkörtlar, med minst ett område större än 2mm.\nN1b: spridning till bröstets lymfkörtlar, som endast kunnat påvisas genom portvaktsbiopsi (sentinel node biopsy).\nN1c: både N1a och N1b uppfyllt.\nN2: spridning till 4-9 av axillens lymfkörtlar, eller förstoring av påverkade lymfkörtlar i bröstet (antingen N2a eller N2b, men ej båda). \nN2a: spridning till 4-9 av axillens lymfkörtlar, med minst ett område större än 2mm.\nN2b: spridning till minst en av bröstets lymfkörtlar, med förstoring av denna/dessa som resultat.\nN3 – någon av följande:\nN3a: spridning till minst 10 av axillens lymfkörtlar, med minst ett område större än 2mm, ELLER spridning till lymfkörtlar vid nyckelbenet inklusive minst ett område större än 2mm.\nN3b: tumörceller påvisade i minst en av axillens lymfkörtlar (med minst ett område större än 2mm) och förstorade lymfkörtlar i bröstet, ELLER spridning till minst fyra av axillens lymfkörtlar (med minst ett område större än 2mm) och mindre mängd tumörceller påvisade vid portvaktsbiopsi.\nN3c: spridning till lymfkörtlar ovan nyckelbenet, med minst ett område större än 2mm.\n\nM\nMX: förekomst av fjärrmetastaser kan ej faställas.\nM0: inga fjärrmetastaser har kunnat påvisas genom bilddiagnostik eller klinisk undersökning.\ncM0(i+): mindre mängd tumörceller har påvisats i blod eller benmärg, eller i lymfkörtlar bortom bröst och portvaktskörtlar (ej större än 0,2mm).\nM1: spridning till andra organ; vanligen skelett, lungor, hjärna eller lever.\n\nStadium     5-årsöverlevnad           TNM                                 Beskrivning\t                                                                                                                          \n0                       99%                      \n                                                Tis N0 M0            Carcinoma in situ. Varken regionalt lymfkörtelengagemang eller fjärrmetastaser har kunnat påvisas.\n                                                                                                                                                     \nI                        92%\n                                                 T1 N0 M0           Tumör som störst 2 cm. Varken regionalt lymfkörtelengagemang eller fjärrmetastaser har kunnat påvisas.\n                                                                                                                                                                \nIIA                     82%\n                                                 T0 N1 M0            Primärtumör har ej kunnat fastställas. Metastaser i regionala lymfkörtlar ipsilateralt. Ingen fjärrmetastasering påvisad.\n                                                 T1 N1 M0            Tumören är som störst 2 cm. Metastaser i regionala lymfkörtlar ipsilateralt. Ingen fjärrmetastasering påvisad.\n                                                 T2 N0 M0            Tumören är 2-5 cm. Varken regionalt lymfkörtelengagemang eller fjärrmetastaser har kunnat påvisas.\n                                               \nIIB                      65%                         \n                                                  T2 N1 M0           Tumören är 2-5 cm. Metastaser i regionala lymfkörtlar ipsilateralt. Ingen fjärrmetastasering påvisad.                                                                                                               \n                                                  T3 N0 M0           Tumören är större än 5 cm. Varken regionalt lymfkörtelengagemang eller fjärrmetastaser har kunnat påvisas.\n                                                                             \t                                    \nIIIA                     47%                              \n                                                   T0 N2 M0          Primärtumör har ej kunnat fastställas. Metastaser i fixerade (icke rörliga) regionala lymfkörtlar ipsilateralt. Ingen fjärrmetastasering påvisad.\n                                                   T1 N2 M0          Tumören är som störst 2 cm. Metastaser i fixerade (icke rörliga) regionala lymfkörtlar ipsilateralt. Ingen fjärrmetastasering påvisad.\n                                                   T2 N2 M0          Tumören är 2-5 cm. Metastaser i fixerade (icke rörliga) regionala lymfkörtlar ipsilateralt. Ingen fjärrmetastasering påvisad.\n                                                   T3 N1-2 M0       Tumören är större än 5 cm. Metastaser i fixerade (icke rörliga) regionala lymfkörtlar ipsilateralt. Ingen fjärrmetastasering påvisad.\t\nIIIB                      44%                          \n                                                    T4 N1-3 M0      •Tumören har invaderat bröstväggen. Regionalt lymfkörtelengagemang. Inga fjärrmetastaser har kunnat påvisas.\n                                                    T1-4 N3 M0      •Oavsett tumörstorlek. Metastasering till ipsilaterala lymfkörtlar i bröstet.  Inga fjärrmetastaser har kunnat påvisas.\n        \t\nIV                        14%                       \n                                                    T1-4 N1-3 M1     Oavsett tumörstorlek eller grad av regionalt lymfkörtelengagemang. Fjärrmetastaser har påvisats.\t\n\n\n",
        "misuse": "TNM-klassifikation kräver data inhämtad med hjälp av högkvalitativa metoder inklusive bilddiagnostik och omfattande lymfkörtelundersökning. ",
        "copyright": "© Cambio Healthcare Systems"
      },
      "en": {
        "purpose": "The American Joint Committee on Cancer (AJCC) TNM staging system reports on the severity of breast cancer based on tumor, lymph node and metastasis characteristics. The characteristics of the size of the tumour, the extent of spread to local lymph nodes and body organs. These aspects are captured in 3 ways that make up the mnemonic TNM: T: Tumour size; N: Number of regional lymph nodes affected and M: whether the cancer has spread/metastasised beyond the primary organ and regional nodes. Each major category is further subdivided to help classify the picture further. These subdivisions are given suffixes or numbered as shown below.",
        "keywords": [
          "TNM breast cancer staging",
          "breast cancer"
        ],
        "use": "The TNM staging system is used with breast cancer patients post biopsy. The system allows clinicians to provide staging and prognosis information on their patients and the TNM staging system for breast cancer is regularly updated through the NCCN (National Comprehensive Cancer Network) breast staging guidelines (3)\n\nBreast cancer staging has several detailed subdivisions which are briefly described below. For more detail, please look at the AJCC staging information. (1)\n\nStaging based on multiple factors including:\n\nPrimary Tumor (T) characteristics\nRegional lymph nodes (N)\n     Clinical\n      Pathological\nDistant metastasis (M)\n\nThe Tumor (T) Node (N) Metastases (M) classification diversifies further in Breast cancer staging as follows:\n\nT\nTX: Primary tumor cannot be assessed.\nT0: No evidence of primary tumor.\nTis: Carcinoma in situ (DCIS, LCIS, or Paget disease of the nipple with no associated tumor mass)\nT1 (includes T1a, T1b, and T1c): Tumor is 2 cm (3/4 of an inch) or less across.\nT2: Tumor is more than 2 cm but not more than 5 cm (2 inches) across.\nT3: Tumor is more than 5 cm across.\nT4 (includes T4a, T4b, T4c, and T4d): Tumor of any size growing into the\nchest wall or skin. This includes inflammatory breast cancer.\n\nN\nAn area of cancer spread \u003c 0.2 mm (or fewer than 200 cells) doesn\u0027t affect the stage, but is recorded with abbreviations (i+ or mol+) that indicate the type of special test used to find the spread but this level of staging does not affect the overall staging classification of the N subset.\nIf the area of cancer spread is \u003e \u003d 0.2 mm (or 200 cells), but still not larger than 2 mm, it is called a micrometastasis. Micrometastases are counted only if there aren\u0027t any larger areas of cancer spread (\u003e 2mm).\n\nNX: Nearby lymph nodes cannot be assessed\nN0: Cancer has not spread to nearby lymph nodes.\nN0(i+): Cancer spread \u003c 200 cells and is \u003c 0.2 mm [\\\"i+\\\" \u003d presence of small numbers of isolated tumor cells) in immunohistochemistry.\nN0(mol+): Cancer cells cannot be seen in underarm lymph nodes but traces of cancer cells were detected using RT-PCR. \nN1: Cancer spread to 1 to 3 axillary (underarm) lymph node(s), and/or tiny amounts of cancer in internal mammary lymph nodes\nN1mi: Micrometastases in 1 to 3 lymph nodes under the arm. The areas of cancer spread in the lymph nodes are 2 mm or less across (but at least 200 cancer cells or 0.2mm across).\nN1a: Cancer has spread to 1 to 3 lymph nodes under the arm with at least one area of cancer spread greater than 2 mm across.\nN1b: Cancer has spread to internal mammary lymph nodes, but this spread could only be found on sentinel lymph node biopsy\nN1c: Both N1a and N1b apply.\nN2: Cancer has spread to 4 to 9 lymph nodes under the arm, or cancer has enlarged the internal mammary lymph nodes (either N2a or N2b, but not both).\nN2a: Cancer has spread to 4 to 9 lymph nodes under the arm, with at least one area of cancer spread larger than 2 mm.\nN2b: Cancer has spread to one or more internal mammary lymph nodes, causing them to become enlarged.\nN3: Any of the following:\nN3a: either:\nCancer has spread to 10 or more axillary lymph nodes, with at least one area of cancer spread greater than 2mm, OR cancer has spread to the lymph nodes under the collar bone (infraclavicular nodes), with at least one area of cancer spread\ngreater than 2mm.\nN3b: either:\nCancer is found in at least one axillary lymph node (with at least one area of cancer spread greater than 2 mm) and has enlarged the internal mammary lymph nodes, OR cancer has spread to 4 or more axillary lymph nodes (with at least one area of cancer spread greater than 2 mm), and tiny amounts of cancer are found in internal mammary lymph nodes on sentinel lymph node biopsy.\nN3c: Cancer has spread to the lymph nodes above the collar bone (supraclavicular nodes) with at least one area of cancer spread greater than 2mm.\n\nM\nMX: Distant spread (metastasis) cannot be assessed.\nM0: No distant spread is found on x-rays (or other imaging tests) or by physical exam.\ncM0(i+): Small numbers of cancer cells are found in blood or bone marrow (found only by special tests), or tiny areas of cancer spread (no larger than 0.2 mm) are found in lymph nodes away from the breast.\nM1: Cancer has spread to distant organs (most often to the bones, lungs, brain, or liver).\n\nStage\tTNM\t            Description\t                                                                                                                 5-year Survival\n0\tTis N0 M0             Carcinoma in situ. \n                                                  No tumor is regional lymph nodes, No distant metastases\t                                                                      99%\nI\tT1 N0 M0\t            Tumor is less than or equal to 2 centimeters, \n                                                  No tumor in regional lymph nodes, No distant metastases                                                                                            92%\nIIA\tT0 N1 M0              No evidence of primary tumor, metastases to movable ipsilateral nodes, \n                   T1 N1 M0              No distant metastases.\n                   T2 N0 M0\t            Tumor is less than or equal to 2 centimeters, metastases to movable ipsilateral    \n                                                  nodes, No distant metastases.\n                                                 Tumor is between 2 and 5 centimeters, No tumor in regional lymph nodes,\n                                                 No distant metastases\t                                                                                                                                                      82%\nIIB\tT2 N1 M0             Tumor is between 2 and 5 centimeters, metastases to movable ipsilateral nodes,\n                   T3 N0 M0             No distant metastases.\n                                                 Tumor is over 5 centimeters, No tumor in regional lymph nodes, No distant metastases.\t                                      65%\nIIIA\tT0 N2 M0              No evidence of primary tumor, metastases to fixed ipsilateral nodes, no distant metastases.\n                   T1 N2 M0             Tumor is less than or equal to 2 centimeters, metastases to fixed ipsilateral nodes, No distant metastases.\n                   T2 N2 M0             Tumor is between 2 and 5 centimeters, metastases to fixed ipsilateral nodes, no distant metastases. \n                   T3 N1, N2 M0      Tumor is over 5 centimeters, metastases to movable or fixed ipsilateral nodes, no distant metastases.\t47%\nIIIB\tT4 Any N M0\nAny T N3 M0\t•\tTumor extends to chest wall, any nodal involvement, no distant metastases.\n•\tAny primary tumor involvement, metastases to ipsilateral internal mammary nodes, no distant metastases.\t44%\nIV\tAny T Any N M1\tAny primary tumor involvement, any nodal involvement, distant metastases.\t14%\n",
        "misuse": "Using the TNM classification alone is not recommended in providing diagnostic assessment. Clinical evidence is required to back up the staging suggestions. ",
        "copyright": "© Cambio Healthcare Systems"
      }
    },
    "otherDetails": {
      "references": "Ref. 1: AJCC Cancer Staging Atlas A Companion to the Seventh Editions of the AJCC Cancer Staging Manual and Handbook\nCarolyn C. Compton David R Byrd; Julio Garcia-Aguilar; American Joint Committee on Cancer Content Provider. New York, NY : Springer New York : Imprint: Springer 2nd ed. 2012\n\nRef. 2: Theriault RL, Carlson RW, Allred C, et al. Breast Cancer, Version 3.2013: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network?: JNCCN. 2013;11(7):753-761.\n\nRef. 3: Regular updates for breast cancer staging and treeatment can be found on the NCCN  (National Comprehensive Cancer Network) website, accessed at: www.nccn.org\n"
    }
  },
  "alertGuideIds": [],
  "executionGuideIds": [
    "TNM_Breast.v1",
    "TNM_Breast_Assessment.v1"
  ],
  "alertBindings": {},
  "termDefinitions": {
    "sv": {
      "id": "sv",
      "terms": {
        "vt0001": {
          "id": "vt0001",
          "text": "Referenser"
        }
      }
    },
    "en": {
      "id": "en",
      "terms": {
        "vt0001": {
          "id": "vt0001",
          "text": "References"
        }
      }
    }
  },
  "resultTemplates": []
}</script>
</head>
<body ng-controller="cds_controller">
<#assign app_help_tag = "def.guides['TNM_Breast.v1'].concept">
<#assign references = "def.terms['vt0001']"/>
<#assign tnm_breast_cancer_staging_entry_cds_data = "data.cds['openEHR-EHR-OBSERVATION.tnm_breast_cancer_staging.v1']">
<#assign tnm_breast_cancer_staging_entry_ehr_data = "data.ehr['openEHR-EHR-OBSERVATION.tnm_breast_cancer_staging.v1']">
<#assign tnm_breast_cancer_staging_entry_def = "def.entries['openEHR-EHR-OBSERVATION.tnm_breast_cancer_staging.v1']">
<#assign tumour_def = tnm_breast_cancer_staging_entry_def + ".elements['/data{at0001}/events{at0002}/data{at0003}/items{at0004}']">
<#assign nodal_involvement_def = tnm_breast_cancer_staging_entry_def + ".elements['/data{at0001}/events{at0002}/data{at0003}/items{at0005}']">
<#assign metastases_def = tnm_breast_cancer_staging_entry_def + ".elements['/data{at0001}/events{at0002}/data{at0003}/items{at0006}']">
<#assign breast_cancer_stage_def = tnm_breast_cancer_staging_entry_def + ".elements['/data{at0001}/events{at0002}/data{at0003}/items{at0007}']">
<#assign event_time_def = tnm_breast_cancer_staging_entry_def + ".elements['/data/events/time']">
<#assign tumour_cds_data = tnm_breast_cancer_staging_entry_cds_data + "[0].elements['/data{at0001}/events{at0002}/data{at0003}/items{at0004}']">
<#assign nodal_involvement_cds_data = tnm_breast_cancer_staging_entry_cds_data + "[0].elements['/data{at0001}/events{at0002}/data{at0003}/items{at0005}']">
<#assign metastases_cds_data = tnm_breast_cancer_staging_entry_cds_data + "[0].elements['/data{at0001}/events{at0002}/data{at0003}/items{at0006}']">
<#assign breast_cancer_stage_cds_data = tnm_breast_cancer_staging_entry_cds_data + "[0].elements['/data{at0001}/events{at0002}/data{at0003}/items{at0007}']">
<#assign event_time_cds_data = tnm_breast_cancer_staging_entry_cds_data + "[0].elements['/data/events/time']">
<#assign tumour_ehr_data = tnm_breast_cancer_staging_entry_ehr_data + "[0].elements['/data{at0001}/events{at0002}/data{at0003}/items{at0004}']">
<#assign nodal_involvement_ehr_data = tnm_breast_cancer_staging_entry_ehr_data + "[0].elements['/data{at0001}/events{at0002}/data{at0003}/items{at0005}']">
<#assign metastases_ehr_data = tnm_breast_cancer_staging_entry_ehr_data + "[0].elements['/data{at0001}/events{at0002}/data{at0003}/items{at0006}']">
<#assign breast_cancer_stage_ehr_data = tnm_breast_cancer_staging_entry_ehr_data + "[0].elements['/data{at0001}/events{at0002}/data{at0003}/items{at0007}']">
<#assign event_time_ehr_data = tnm_breast_cancer_staging_entry_ehr_data + "[0].elements['/data/events/time']">
<#assign tnm_breast_cancer_assessment_entry_cds_data = "data.cds['openEHR-EHR-EVALUATION.tnm_breast_cancer_assessment.v1']">
<#assign tnm_breast_cancer_assessment_entry_def = "def.entries['openEHR-EHR-EVALUATION.tnm_breast_cancer_assessment.v1']">
<#assign _5_year_survival_rates_def = tnm_breast_cancer_assessment_entry_def + ".elements['/data{at0001}/items{at0002}']">
<#assign _5_year_survival_rates_cds_data = tnm_breast_cancer_assessment_entry_cds_data + "[0].elements['/data{at0001}/items{at0002}']">

<script> 
angular.module('cds_app').controller('TNM_breast_cancer_Ctrl', function($scope, $window){
  $scope.$on('json_loaded', function(){
    $scope.${event_time_ehr_data}.value.value = new Date().toISOString();
	$scope.${tumour_ehr_data}.value.selection = $scope.findMin($scope.${tumour_def});
	$scope.${nodal_involvement_ehr_data}.value.selection = $scope.findMin($scope.${nodal_involvement_def});
	$scope.${metastases_ehr_data}.value.selection = $scope.findMin($scope.${metastases_def});
  });
});
</script>

<div ng-show="ready" ng-controller="TNM_breast_cancer_Ctrl">
<div class="header">
  <h1>{{def.concept.name}}</h1>
  <h2>{{def.concept.description}}</h2>
  <div class="help-tip">
	<p>{{${app_help_tag}.description}}</p>
  </div>
</div>

<div class="card">
  <div class="row collapse" title="{{${tumour_def}.description}}">
    <div class="medium-6 columns">
      <label>{{${tumour_def}.name}}</label>
      </div>
      <label class="medium-6 columns">
        <select ng-model="${tumour_ehr_data}.value.selection" ng-options="key as (key.charAt(0) + ' - ' + desc) for (key, desc) in ${tumour_def}.selections" ng-change="execute()" ng-model-options="{ updateOn: 'default blur', debounce: { default: 500, blur: 0 } }">
        </select>
      </label>
    </div>
	<div class="row collapse" title="{{${nodal_involvement_def}.description}}">
    <div class="medium-6 columns">
      <label>{{${nodal_involvement_def}.name}}</label>
      </div>
      <label class="medium-6 columns">
        <select ng-model="${nodal_involvement_ehr_data}.value.selection" ng-options="key as (key.charAt(0) + ' - ' + desc) for (key, desc) in ${nodal_involvement_def}.selections" ng-change="execute()" ng-model-options="{ updateOn: 'default blur', debounce: { default: 500, blur: 0 } }">
        </select>
      </label>
    </div>
	<div class="row collapse" title="{{${metastases_def}.description}}">
    <div class="medium-6 columns">
      <label>{{${metastases_def}.name}}</label>
      </div>
      <label class="medium-6 columns">
        <select ng-model="${metastases_ehr_data}.value.selection" ng-options="key as (key.charAt(0) + ' - ' + desc) for (key, desc) in ${metastases_def}.selections" ng-change="execute()" ng-model-options="{ updateOn: 'default blur', debounce: { default: 500, blur: 0 } }">
        </select>
      </label>
    </div>
<div class="row collapse" title="{{${breast_cancer_stage_def}.description}}" id="displayresult1">
  <div class="medium-6 columns">
    <label><b>{{${breast_cancer_stage_def}.name}}: </b></label>
  </div>
  <div class="medium-6 columns" style="text-align: center;">
    <label>{{${breast_cancer_stage_cds_data}.value.symbol.value}}</label>
  </div>
</div>
<div class="row collapse" title="{{${_5_year_survival_rates_def}.description}}" id="displayresult2">
  <div class="medium-6 columns">
    <label><b>{{${_5_year_survival_rates_def}.name}}: </b></label>
  </div>
  <div class="medium-6 columns" style="text-align: center;">
    <label>{{${_5_year_survival_rates_cds_data}.value.symbol.value}}</label>
  </div>
</div>
</div>
</div>

<div class="row"><div class="medium-12 columns"></div></div>
<br /><br />
<div class="row collapse" title="{{${references}.text}}" style="font-size: 85%;">
  <div class="medium-11 medium-offset-1 column">
    <label>{{${references}.text}}:</label>
  </div>
</div>
<div class="references1">
<div class="row collapse">
      <div class="medium-11 medium-offset-1 column">
        <li>
          <i><a>Carolyn C. Compton David R Byrd; Julio Garcia-Aguilar; AJCC Cancer Staging Atlas A Companion to the Seventh Editions of the AJCC Cancer Staging Manual and Handbook American Joint Committee on Cancer Content Provider. New York, NY : Springer New York : Imprint: Springer 2nd ed. 2012</a></i>
        </li>
      </div>
    </div>
<div class="row collapse">
      <div class="medium-11 medium-offset-1 column">
        <li>
          <i><a href="https://www.ncbi.nlm.nih.gov/pubmed/23847214">Theriault RL, Carlson RW, Allred C, et al. Breast Cancer, Version 3.2013: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network?: JNCCN. 2013;11(7):753-761.</a></i>
        </li>
      </div>
    </div>
<div class="row collapse">
      <div class="medium-11 medium-offset-1 column">
        <li>
          <i><a href=" www.nccn.org">Regular updates for breast cancer staging and treatment can be found on the NCCN (National Comprehensive Cancer Network) website, accessed at: www.nccn.org</a></i>
        </li>
      </div>
    </div>
  </div>

<style>
  html, body {
    height:100%;
    width: 100%;
  }
  body {
    font-family: sans-serif;
    font-weight: 300;
    color: #333;
    background: #ecf0f9;
    padding: 1em;
    -webkit-font-smoothing: antialiased;
  }
  h1 {
    font-weight: 600;
    text-align: center;
  }
  h2 {
    text-align: center;
    font-weight: 300;
    font-size: 22px;
    font-style: italic;
  }
  .header {
    margin-bottom: 2em;
  }
  .card {
    background-color: #fdfdfd;
    box-shadow: 0 3px 6px rgba(0,0,0,0.16), 0 3px 6px rgba(0,0,0,0.23);
    margin: 10px auto 0 auto;
    padding: 1em;
    width: 50%;
    overflow: hidden;
  }
  .help-tip{
      position: absolute;
      top: 18px;
      right: 18px;
      text-align: center;
      background-color: #BCDBEA;
      border-radius: 50%;
      width: 24px;
      height: 24px;
      font-size: 14px;
      line-height: 26px;
      cursor: default;
  }
  .help-tip:before{
      content:'?';
      font-weight: bold;
      color:#fff;
  }
  .help-tip:hover p{
      display:block;
      transform-origin: 100% 0%;
      -webkit-animation: fadeIn 0.3s ease-in-out;
      animation: fadeIn 0.3s ease-in-out;
  }
  .help-tip p{	/* The tooltip */
      display: none;
      text-align: left;
      background-color: #1E2021;
      padding: 20px;
      width: 300px;
      position: absolute;
      border-radius: 3px;
      box-shadow: 1px 1px 1px rgba(0, 0, 0, 0.2);
      right: -4px;
      color: #FFF;
      font-size: 13px;
      line-height: 1.4;
      z-index: 9999;
  }
  .help-tip p:before{ /* The pointer of the tooltip */
      position: absolute;
      content: '';
      width:0;
      height: 0;
      border:6px solid transparent;
      border-bottom-color:#1E2021;
      right:10px;
      top:-12px;
  }
  .help-tip p:after{ /* Prevents the tooltip from being hidden */
      width:100%;
      height:40px;
      content:'';
      position: absolute;
      top:-40px;
      left:0;
  }
  .references1{
    font-size: 70%;
  }
  /* CSS animation */
  @-webkit-keyframes fadeIn {
      0% { 
          opacity:0; 
          transform: scale(0.6);
      }

      100% {
          opacity:100%;
          transform: scale(1);
      }
  }
  @keyframes fadeIn {
      0% { opacity:0; }
      100% { opacity:100%; }
  }
  #displayresult1 {
    background-color: #e6e6e6; 
    padding-top: 3px;
    padding-bottom: 3px;
	padding-left: 3px;
    font-size: 90%;
  }
  #displayresult2 {
    background-color: #f2f2f2;
    padding-top: 3px;
    padding-bottom: 3px;
	padding-left: 3px;
    font-size: 90%;
  }
  select, label:not(#h-fix) {
    margin-bottom: 10px;
</style>



</body></html>